Roivant Sciences Ltd. engages in the biopharmaceutical business, which engages in the development of transformative medicine. The Company’s pipeline includes brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis and cutaneous sarcoidosis; IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. The company also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business.
Follow-Up Questions
Roivant Sciences Ltd のCEOは誰ですか？
Mr. Matthew Gline は Roivant Sciences Ltd の Chief Executive Officer で、2017 から在籍しています。
